A Phase 1 study evaluating the self-amplifying mRNA H5N1 vaccine ARCT-2304 found that spacing doses eight weeks apart produced stronger, longer-lasting antibody responses than a four-week interval, extending the signal window for early immunogenicity optimization. The data add to a growing emphasis on schedule-dependent durability for emerging influenza platforms. Separately, Eli Lilly’s oral GLP-1 candidate orforglipron won EU human medicines committee (CHMP) endorsement, positioning the company to challenge Novo Nordisk’s Wegovy with a new oral option. The regulatory step keeps pressure on competitors as payers and clinicians weigh convenience alongside efficacy and safety. In liver disease, new private funding and preclinical momentum continued with Estuary Biotherapeutics, which unveiled a $103 million push supporting two gene therapy candidates for autosomal dominant polycystic kidney disease (ADPKD)-associated inherited kidney disease. While not yet clinical, the financing underscores sustained investor appetite for next-generation genetic therapeutics. Taken together, the updates show regulators and investors continuing to reward both schedule refinement in vaccines and platform diversification in metabolic and genetic medicine.